233results about How to "Reduce seizures" patented technology

All low-temperature processes are used to fabricate a variety of semiconductor devices in a substrate the does not include an epitaxial layer. The devices include a non-isolated lateral DMOS, a non-isolated extended drain or drifted MOS device, a lateral trench DMOS, an isolated lateral DMOS, JFET and depletion-mode devices, and P-N diode clamps and rectifiers and junction terminations. Since the processes eliminate the need for high temperature processing and employ “as-implanted” dopant profiles, they constitute a modular architecture which allows devices to be added or omitted to the IC without the necessity of altering the processes used to produce the remaining devices.

All low-temperature processes are used to fabricate a variety of semiconductor devices in a substrate the does not include an epitaxial layer. The devices include a non-isolated lateral DMOS, a non-isolated extended drain or drifted MOS device, a lateral trench DMOS, an isolated lateral DMOS, JFET and depletion-mode devices, and P-N diode clamps and rectifiers and junction terminations. Since the processes eliminate the need for high temperature processing and employ “as-implanted” dopant profiles, they constitute a modular architecture which allows devices to be added or omitted to the IC without the necessity of altering the processes used to produce the remaining devices.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present invention is directed to a method for reducing the onset or incidence of gelation / fibrillation / aggregation during the up- and down-stream processing and purification of peptides, polypeptides and proteins analogs and / or derivatives thereof, including Glucagon-Like Peptides (GLPs). More particularly, the present invention relates to methods of processing and purifying such peptides, polypeptides and proteins in the presence of tris(hydroxymethyl)aminomethane.

All low-temperature processes are used to fabricate a variety of semiconductor devices in a substrate the does not include an epitaxial layer. The devices include a non-isolated lateral DMOS, a non-isolated extended drain or drifted MOS device, a lateral trench DMOS, an isolated lateral DMOS, JFET and depletion-mode devices, and P-N diode clamps and rectifiers and junction terminations. Since the processes eliminate the need for high temperature processing and employ “as-implanted” dopant profiles, they constitute a modular architecture which allows devices to be added or omitted to the IC without the necessity of altering the processes used to produce the remaining devices.

Provided is a soft flexible oral appliance having protuberances that mimic naturally occurring dental Tori. An upper, palatial appliance and a lower, mandibular appliance may be used in conjunction or separately to alleviate a variety of disorders, improve facial tone, and increase physical performance. The appliances are lightweight, thin, and do not prohibit normal speech patterns when in use. Small protuberances are strategically molded along key surfaces of each appliance to stimulate nerves in the tongue and affect forward protrusion. Forward positioning of the tongue dilates the airways of the throat improving breathing while the use is sleeping, playing sports, or talking. It also reduces bruxing, or grinding of the teeth. A method is further provided, for adding protuberances to other types of oral appliances, thereby conferring some of the benefits listed above on appliances originally intended for other dental uses.

All low-temperature processes are used to fabricate a variety of semiconductor devices in a substrate the does not include an epitaxial layer. The devices include a non-isolated lateral DMOS, a non-isolated extended drain or drifted MOS device, a lateral trench DMOS, an isolated lateral DMOS, JFET and depletion-mode devices, and P-N diode clamps and rectifiers and junction terminations. Since the processes eliminate the need for high temperature processing and employ “as-implanted” dopant profiles, they constitute a modular architecture which allows devices to be added or omitted to the IC without the necessity of altering the processes used to produce the remaining devices.

Devices, systems and methods are disclosed that allow a patient to self-treat epileptic seizures by electrical noninvasive stimulation of a vagus nerve. The system comprises a handheld stimulator that is applied to the surface of the patient's neck, wherein the stimulator comprises or is joined to a smartphone. A camera of the smartphone may be used to position and reposition the stimulator to a particular location on the patient's neck. The system may also comprise a base station that is used to meter the charging of a rechargeable battery within the stimulator. The base station and stimulator transmit data to one another regarding the status of a stimulation session.

The present invention provides a helicid powder injection and its preparation method. Every powder injection contains 25-600 mg of helicid, and the rest is medicinal auxiliary material for injection. It has good stability, can be stored for 3 years at normal temperature, its irritation is small, and its injection site has no clear change or light hyperemia, and its sedation effect is good, and its convulsion-resisting action is strong, it can obviously reduce coriamyrtin convulsion incidence rate, prolong generative latent period, reduce frequency of attack and shorten time and process of attack. The tests show that said helicid powder injection has the strong action of stopping pain and relieving inflammation.

A helicidium softcapsule is composed of the liquid medicine and shell material, and features that said dliquid medicine is prepared from superfine helicidum particles and medicinal auxiliary.

Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking one or more antiepileptic drugs that works via GABA receptor agonism. Preferably the AED is stiripentol. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the S-enantiomer are formulated to control ketone body levels in a subject. The non-racemic mixture of BHB is enriched with the S-enantiomer to modulate the effect of ketone bodies in the subject and control the rate at which ketosis is achieved. In some aspects a composition for controlling ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate, wherein the non-racemic mixture contains from about 52% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer and from about 48% to about 1% by enantiomeric equivalents of R-beta-hydroxybutyrate enantiomer.

(1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).

The present disclosure relates to methods of reducing the onset of allergies. In certain embodiments, the method includes administering to an infant a nutritional composition that includes a fat or lipid source, a carbohydrate source, a protein source comprising whey and casein proteins and, optionally, a probiotic. In certain embodiments, the whey:casein ratio in the protein source is from about 50:50 to about 70:30 and the degree of hydrolysis of the proteins included in the protein source is from about 4% to about 10%.

The invention discloses Chinese medicinal magneto-therapy externally applied plaster applied to acupuncture points and used for treating asthma. The externally applied plaster comprises the following components in part by weight: 10 to 30 parts of white mustard seed, 10 to 30 parts of corydalis tuber, 10 to 20 parts of euphorbia kansui, 10 to 20 parts of roasted asarum, 5 to 15 parts of roasted ephedra, 5 to 15 parts of unprocessed pinellia tuber, 5 to 10 parts of roasted liquorice, 10 to 20 parts of roasted sessile stemona root, 5 to 10 parts of cinnamon, 5 to 10 parts of semen lepidii, 60 to 80 parts of ginger juice, 10 to 15 parts of roasted gleditsia sinensis, 1 to 1.5 parts of musk, 10 to 15 parts of arisaema cum bile, 10 to 20 parts of fritillaria, 10 to 20 parts of earthworm, 1 to 5 parts of borneol, 10 to 20 parts of bitter almond, 10 to 20 parts of swallowwort rhizome, and 10 to 20 parts of roasted common coltsfoot flower. The externally applied plaster is characterized by consisting of a flaky sticking matrix, a magnetic block and Chinese medicinal ointment sequentially from inside to outside. The externally applied plaster has the characteristics of scientific compatibility of Chinese medicaments, reasonable content of each component, simplicity in preparation method, safety and convenience in use, definite and obvious curative effect and the like. By matching acupuncture point application, the effective rate of the externally applied plaster for treating the asthma reaches 90 percent.

The present invention is directed to a method for reducing the onset or incidence of gelation / fibrillation / aggregation during the up- and down-stream processing and purification of peptides, polypeptides and proteins analogs and / or derivatives thereof, including Glucagon-Like Peptides (GLPs). More particularly, the present invention relates to methods of processing and purifying such peptides, polypeptides and proteins in the presence of tris(hydroxymethyl)aminomethane.

Methods and compositions for preventing memory loss and reducing the onset of Alzheimer's disease and the pathological symptoms associated therewith including memory loss, reduced cognitive function and dementia are provided. These methods and compositions comprise dosage regimens that provide for the daily administration of effective amounts of Vitamin C, Vitamin E, DHA, and Curcumin.

The invention provides a traditional Chinese medicinal preparation for treating a stable phase chronic obstructive pulmonary disease. The traditional Chinese medicinal preparation is prepared from the following medicinal materials in part by weight: 10 to 20 parts of medlar, 3 to 5 parts of prepared common monkshood daughter root, 3 to 5 parts of cinnamon, 10 to 20 parts of malaytea scurfpea fruit, 10 to 20 parts of south dodder seed, 10 to 20 parts of epimedium, 10 to 20 parts of Chinese angelica, 10 to 20 parts of red paeony root, 10 to 20 parts of szechuan lovage rhizome, 10 to 20 parts of root of rehmannia, 10 to 20 parts of amur corktree bark, 10 to 20 parts of white mulberry root bark, 20 to 30 parts of astragalus, 5 to 10 parts of liquoric root, 10 to 20 parts of aster, 5 to 10 parts of dried ginger, 5 to 10 parts of fritillary and 5 to 10 parts of peeled ginkgo seed. The traditional Chinese medicinal preparation can be prepared into formulations such as capsule preparations, granules, tablets, pills, oral liquid preparations and the like. The traditional Chinese medicinal preparation is a pure traditional Chinese medicinal preparation and does not have toxic or side effect. When the medicaments are used together, the traditional Chinese medicinal preparation has the effects of tonifying qi, nourishing yin, warming yang, supplementing lung, invigorating the spleen, nourishing kidney, relieving cough and asthma, eliminating phlegm, and treating both the symptoms and diseases. The traditional Chinese medicinal preparation has the obvious effect of treating the stable-phase chronic obstructive pulmonary disease and has the effect of treating diseases such as bronchial asthma and the like.

The present invention provides a skin cream which can be used by most individuals on a daily basis to improve the quality of skin tone. The skin cream of the present invention comprises at least one anti-oxidant, an anti-inflammatory agent, an exfoliant, and an agent to protect against UV irradiation. In addition, the skin cream of the present invention may comprise oils, creams, and / or other compounds to promote adsorption of the active ingredients and to increase vibrancy of the skin tone. For example, in an embodiment, the skin cream of the present invention comprises: (a) dimethylaminoethanol (DMAE), (b) α-lipoic acid, (c) lactic acid, (d) retinol, (e) zinc or titanium oxide, and (f) vitamin C, wherein components (a), (b), (c), (d), (e) and (f) are in amounts such that application of the cream to an individual increases the thickness of collagen bundles in the individual's skin.

The invention discloses a closed-loop system used for epilepsy treatment. The closed-loop system includes an electroencephalogram signal amplification module, a control unit, a stimulation module and a video module, wherein the electroencephalogram signal amplification module is used for collecting an electroencephalogram signal of a target to be detected; the state of the electroencephalogram signal is judged by the control unit, and the control unit controls the stimulation module to generate pulse current to stimulate the target to be detected to restrain epileptic seizure and further, closed loop regulation and control can be realized. The closed-loop system has the following functions: multichannel data with high sampling frequency can be obtained in a real-time manner through an amplifier, real-time drawing is carried out, epilepsy early warning is realized based on electroencephalogram signals, and epilepsy can be automatically restrained through electrostimulation with designated parameters after early warning. The invention provides a close-loop electrostimulation treatment system for patients suffering from intractable epilepsy, and the closed-loop system effectively reduces frequency of epileptic seizure, alleviates the intensity of epileptic seizure, and improves the living quality of patients.

(1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).

Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the R-enantiomer are formulated to increase ketone body level in a subject. The non-racemic mixture of BHB is enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer sufficient to provide alternative benefits as discussed herein. In some aspects a composition for increasing ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 55% to 98% by enantiomeric equivalents of the R-beta-hydroxybutyrate and from about 45% to about 2% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer.

Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.

A knife with a handle capable of adjustable weight configurations. The handle is hollow such that the weight balance between the handle and blade may be adjusted through the selective use of one or more removable weights that form part of an axially oriented weight mounting assembly. A user may add or remove weights until a desired knife balance is achieved.

The invention provides a special clinical nutrition formula for epileptics. The nutrition formula comprises the following components in parts by weight: 10-22 parts of protein, 32-55 parts of fat, 6-25 parts of carbohydrate, 7-9 parts of dietary fiber, 0.6-1.2 parts of major elements, 0.01-0.04 part of trace elements, 0.005-0.03 part of fat-soluble vitamin, 0.008-0.2 part of water-soluble vitamin,0.05-1 part of dietary essence, 0.06-2 parts of medicinal and food homologous ingredients, and 0.005-2 parts of new source food. The invention further provides a preparation method of the clinical nutrition formula. The clinical nutrition formula can cure epilepsy and can relieve the side effects of ketogenic diet.

The present invention relates to one kind of composite beverage and its preparation process. The composite beverage is prepared with wolfberry fruit, chrysanthemum, cassia seed, mulberry leaf and haw in certain weight proportion. It has the health functions of clearing away liver-fire to treat eye diseases, dispelling wind and heat, invigorating kidney and benefiting qi, and possesses obvious effect of treating eye fatigue, blurring eyesight, myopia, etc. The health beverage has no side effect.

Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the S-enantiomer are formulated to control ketone body levels in a subject. The non-racemic mixture of BHB is enriched with the S-enantiomer to modulate the effect of ketone bodies in the subject and control the rate at which ketosis is achieved. In some aspects a composition for controlling ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate, wherein the non-racemic mixture contains from about 52% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer and from about 48% to about 1% by enantiomeric equivalents of R-beta-hydroxybutyrate enantiomer.